What Happened
The Medicines and Healthcare products Regulatory Agency (MHRA) has alerted patients about the potential dispensing of counterfeit Mounjaro (tirzepatide) KwikPen 15mg solutions for injection from The Private Pharmacy Clinic in Birmingham. The affected batch number is D873576, which is legitimate for the genuine Mounjaro KwikPen 7.5mg, indicating that only the 15mg pens are impacted.
Why It Matters
This warning is crucial as the counterfeit pens may not be sterile, despite containing the active substance tirzepatide. Dr. Alison Cave, Chief Safety Officer at the MHRA, emphasized the importance of checking batch numbers and advised patients to stop using any affected pens immediately. The counterfeit issue raises concerns about patient safety and the integrity of pharmaceutical products.
What’s Next
In addition to addressing counterfeit products, the UK government is implementing new financial incentives for doctors prescribing Mounjaro. Starting in April 2026, GPs will receive up to £3,000 annually for prescribing the drug, aimed at increasing access for patients struggling with obesity. This initiative is part of a broader strategy to combat obesity, which affects a significant portion of the adult population in England. However, access to Mounjaro will remain limited to those with severe obesity and specific health conditions, with expectations to expand eligibility in the coming years.